Irhythm Technologies Inc - IRTC STOCK NEWS

iRhythm Technologies (NASDAQ:IRTC) presented new real-world data from the AVALON study at HRS2025, demonstrating the clinical superiority of their Zio long-term continuous monitoring (LTCM) service. The study analyzed 428,707 commercially insured patients, showing Zio LTCM achieved:

- Highest diagnostic yield (26.5%) compared to other monitoring services
- 2.04x higher likelihood of arrhythmia diagnosis vs. Holter monitors
- Lowest likelihood of repeat testing within 180 days
- Reduced cardiovascular events risk within 1 year

The Zio LTCM service includes a patch-based ECG monitor capturing 14 days of continuous data and the ZEUS system with FDA-cleared AI algorithm. The study expands on previous CAMELOT findings in Medicare patients, now confirming benefits in younger, commercially insured populations (mean age: 46 years).

iRhythm Technologies (NASDAQ:IRTC), a digital health care company specializing in disease detection, prevention, and prediction solutions, has scheduled its first quarter 2025 financial results announcement for May 1, 2025, after market close.

The company will host a conference call with management at 1:30 p.m. PT / 4:30 p.m. ET on the same day. Investors can access both live and archived versions of the conference call through the 'Quarterly Results' section on iRhythm's investor website at investors.irhythmtech.com.

iRhythm Technologies (NASDAQ:IRTC) has released its 2024 Corporate Sustainability Report, showcasing the company's progress in building a sustainable and inclusive future. The report focuses on four key pillars:

• Quality and Sustainable Technology Innovation: Enhanced quality systems, improved EHR integration, secured strategic licensing, and formed an AI Governance Committee
• Access and Health Equity: Expanded to four European countries and received Japanese regulatory approval for Zio® 14-day ECG monitoring system
• Workforce and Inclusion: Refreshed core values, revised code of conduct, and introduced new employee recognition programs
• Environmental Impact: Completed Scope 3 emissions inventory, achieved 89.5% landfill waste diversion, obtained ISO 14001:2015 certification, and was named to Newsweek's America's Greenest Companies 2025

Turing Medical has appointed Kevin King, former CEO of iRhythm Technologies, as its new President and Chief Executive Officer. King brings over 30 years of experience in healthcare and technology, having previously led companies like Affymetrix and Thomson Reuters Healthcare.

The company, focused on precision brain mapping and targeting technologies, is developing advanced functional connectivity MRI processing techniques. Under King's leadership, Turing Medical plans to launch a clinical trial of its PACE Therapy for Treatment Resistant Depression, integrating their Bullsai platform with minimally invasive neuromodulation therapy.

Recent company achievements include FDA 510(k) clearance for the Bullsai platform, an automated cloud-based system for neurosurgical planning, and successful marketing of FIRMM and FIRMM-pix MRI motion monitoring software solutions since 2022.

iRhythm Technologies (NASDAQ:IRTC) presented significant findings from two large real-world studies at ACC.25, analyzing over 1.1 million patients using Zio® long-term continuous monitoring (LTCM) devices. The research revealed critical limitations in traditional 24-48 hour Holter monitoring.

Key findings show that 64% of actionable arrhythmias in patients with daily symptoms went undetected in the first 48 hours of monitoring. Non-daily symptom patients showed higher arrhythmia yield (80.9%) compared to daily-symptom patients (69.1%). The study also found that less than 20% of patients documented symptoms coinciding with arrhythmic episodes, and over half of atrial fibrillation cases were asymptomatic.

The research challenges conventional monitoring approaches and supports the benefits of Zio LTCM's extended 14-day monitoring period. With approximately 16 million Americans experiencing arrhythmias and undiagnosed atrial fibrillation costing the U.S. $3 billion annually, these findings have significant implications for clinical care and payer policies.

iRhythm Technologies (NASDAQ: IRTC) reported strong Q4 2024 results with revenue of $164.3 million, up 24.0% year-over-year, and improved gross margin of 70.0%. The company narrowed its net loss to $1.3 million, a $37.4 million improvement from Q4 2023.

For full-year 2024, revenue grew 20.1% to $591.8 million with gross margin reaching 68.9%. Annual net loss improved to $113.3 million from $123.4 million in 2023. The company maintained a strong cash position of $535.6 million at year-end.

Looking ahead, iRhythm provided 2025 guidance projecting revenue between $675-685 million and adjusted EBITDA margin of 7.0-8.0%. The company highlighted record new account onboarding and successful expansion into international markets, while maintaining positive cash flow for three consecutive quarters.

iRhythm Technologies (NASDAQ:IRTC) has scheduled its fourth quarter and full year 2024 financial results announcement for February 20, 2025, after market close. The digital health care company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results. Investors and interested parties can access both live and archived versions of the conference call through the 'Quarterly Results' section on the company's investor website at investors.irhythmtech.com.

iRhythm Technologies (NASDAQ:IRTC) announced preliminary Q4 2024 operational highlights, expecting full-year 2024 revenue to exceed their previous guidance of $587.5 million. The company achieved record new account openings for both Zio monitor and Zio AT in Q4 2024, with strong contributions from national accounts.

Key developments include launching four healthcare systems on Epic Aura in Q4 2024, with broader U.S. rollout planned for 2025, and initiating Zio monitor home enrollment shipments. The company presented five studies at the American Heart Association, demonstrating Zio Monitor's effectiveness and patient satisfaction.

For 2025, iRhythm projects revenue between $675-685 million. The company expanded internationally into four European countries, received Japanese regulatory approval, and partnered with BioIntelliSense. Future focus includes expanding into primary care channels and enhancing quality systems.

iRhythm Technologies (NASDAQ:IRTC), a digital health care company specializing in disease detection, prediction, and prevention solutions, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management team will deliver a presentation on Monday, January 13, 2025, at 4:30 p.m. Pacific Time/7:30 p.m. Eastern Time.

Interested investors and stakeholders can access both live and archived versions of the presentation through the 'Events & Presentations' section on iRhythm's investor website at investors.irhythmtech.com.